Arlevo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arlevo

Quick Facts

Property Description
Active ingredient Levocetirizine dihydrochloride
Form Oral tablet and oral solution
Pharmacological class Second-generation H₁-receptor antagonist
General purpose Relief of common allergy symptoms
Origin Synthetic; isolated R-enantiomer of cetirizine

Arlevo: Identity, Origin, and Pharmaceutical Classification

Arlevo is a medicine containing the active substance Levocetirizine dihydrochloride, which is recognized as a second-generation H₁-receptor antagonist belonging to the antihistamine pharmacological class. This classification is clinically supported for providing highly effective relief from allergy symptoms while exhibiting a lower potential for central nervous system effects, such as sedation, compared to older-generation agents.

The drug is chemically derived as the isolated R-enantiomer of the related compound, cetirizine (the active ingredient in Zyrtec). This focus on the single active isomer means the medicine is formulated to concentrate its therapeutic action, a structural feature characterized by high potency and selectivity for the histamine H₁ receptor.

Composition and Available Dosage Forms

The medicine is formulated as a single-ingredient product intended for oral administration. It is available as an immediate-release oral tablet and an oral solution, with the liquid form commonly used for administration to patient groups who may have difficulty swallowing tablets.

High-Level Purpose of Levocetirizine Dihydrochloride

The principal function of Levocetirizine dihydrochloride is to achieve sustained relief and suppression of general discomfort resulting from allergic symptoms, such as the persistent itching and congestion caused by seasonal or year-round allergies. The drug achieves this by acting as a powerful selective inhibitor that blocks the effects of histamine on its receptor sites. This targeted mechanism is recognized as providing prompt and long-lasting relief from common allergic manifestations.

What side effects are possible with Arlevo?

Possible Side Effects and Safety Information

Arlevo (levofloxacin) is associated with an official regulatory warning regarding serious, disabling, and potentially irreversible adverse reactions. This summary is based strictly on government regulatory documents (e.g., FDA, EMA).

Adverse Reaction Scope

Classification Examples of Documented Reactions
Common (ge 1/100) Nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Serious Adverse Reactions Tendinitis, tendon rupture (Achilles most common), peripheral neuropathy (nerve damage, potentially lasting), central nervous system effects (seizures, confusion, psychosis), aortic aneurysm and dissection, severe hepatotoxicity/liver failure, and life-threatening allergic reactions (anaphylaxis).
System-Organ Classes Involved Musculoskeletal and Connective Tissue Disorders, Nervous System Disorders, Cardiac Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Safety Restrictions and Vulnerable Populations

  • Mandatory Restrictions (Contraindications): The medicine is officially contraindicated in patients with a known history of hypersensitivity to fluoroquinolones, a history of fluoroquinolone-associated tendon disorders, or myasthenia gravis, as it may worsen muscle weakness.
  • Population-Specific Concerns:
    • Older Adults (Over 60): Have an increased risk of developing severe tendon disorders and may be more susceptible to QTc prolongation and severe hepatotoxicity.
    • Renal Impairment: Requires dose adjustment due to slower drug clearance, which increases the risk of side effects.
    • Pediatric Patients: Generally not recommended for use in children under 18 due to the risk of joint and tendon damage.
  • Exposure Patterns: Tendon damage may occur soon after starting treatment (within 48 hours) or be delayed for several months after the medicine is stopped. Disabling nerve and CNS effects can also occur rapidly.

The official safety documents structure the understanding of risks by separating common, mild reactions from rare, critical adverse events that are associated with a formal regulatory warning. This structure emphasizes that for certain mild infections, the potential for disabling risks may outweigh the benefits, requiring strict limitations on use.

Overdose and Emergency Response

Official Regulatory Statements on Overdose

The official overdose profile for this medication is formally documented in regulatory sources and addresses specific manifestations and emergency procedures. The differences in presentation are formally documented as a population-specific consideration.

Feature Official Regulatory Statement
Documented Manifestations The primary manifestation in adults is listed as drowsiness. In children, the initial presentation includes agitation and restlessness, which may be followed by drowsiness.
Antidote Status No known specific antidote to the active substance is documented in the prescribing information.
Management Management is restricted to symptomatic or supportive treatment, as officially stated.

When to Seek Urgent Help

Immediate medical help must be sought for any suspected overdose. Regulator-mandated actions include contacting a Poison Control Center immediately. Urgent attention is required by calling emergency services (such as 911) for severe presentations. These severe outcomes include collapse, seizures, trouble breathing, or the inability to be awakened.

Procedural information also formally notes that the drug is not effectively removed by dialysis unless a dialyzable agent has been concomitantly ingested. This constraint defines the limitations of specific intervention methods in overdose situations.

Therapeutic Uses of Arlevo

What Arlevo Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed to address conditions presenting with acute or episodic symptoms. Arlevo is commonly used for managing symptomatic distress associated with Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Chronic Idiopathic Urticaria.

It is primarily used for managing symptom clusters that may appear suddenly or fluctuate, such as nasal-related symptoms like sneezing, runny nose, and itching, along with associated ocular discomfort and persistent skin reactions. This support generally helps patients cope more steadily with difficult episodes and contributes to improved comfort during periods of heightened symptoms.

Symptom Domains and Supportive Benefits

Symptom Type Condition Context Therapeutic Benefit
Pruritus (Itching) Chronic Idiopathic Urticaria Helps reduce the overall symptom load.
Rhinorrhea Allergic Rhinitis Supports day-to-day comfort.
Weals/Hives Dermal Manifestations Assists with functional stability.

The drug is relevant when supportive symptom management is appropriate and symptoms interfere with routine activities. This medication is commonly used when symptoms intensify and supportive relief is needed, and may provide support during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility for Arlevo (Levocetirizine)

This medicine's official eligibility is defined by age, organ function, and specific medical history, according to regulatory documentation.

Populations for whom use is allowed (as stated in label):

  • Adults and Adolescents: Individuals 12 years of age and older.
  • Children: Individuals 6 months of age and older.

Populations for whom use is contraindicated:

  • Patients with End-Stage Renal Disease (ESRD), defined as a Creatinine Clearance (CLCR) less than 10 mL/min, or patients undergoing hemodialysis.
  • Children 6 months to 11 years of age with impaired renal function (any degree).
  • Patients with known hypersensitivity to levocetirizine, its related compound cetirizine, or any piperazine derivatives.

Age-Related Eligibility Rules

Age Group Eligibility Status Restriction Context (as documented)
Adults and Adolescents Approved Use is restricted based on renal impairment status.
Children under 6 months Use Not Established Safety and efficacy have not been established.
Children < 6 years Not Recommended The tablet formulation is not recommended; a liquid formulation is necessary for appropriate dose adaptation.

Condition-Specific Eligibility Rules

  • Renal Impairment (Adults ge 12 years): Use is conditional and requires dose adjustment based on the degree of impairment (mild, moderate, or severe).
  • Comorbidities Requiring Caution: Caution is explicitly advised for patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia) or those with epilepsy due to the risk of seizure aggravation.
  • Pregnancy and Lactation: Caution should be exercised during pregnancy. Use during lactation is not recommended due to the drug's excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for levocetirizine dihydrochloride is defined by specific pharmacokinetic (PK) and pharmacodynamic (PD) interactions detailed in government documentation. This information establishes necessary boundaries for co-administration.

Interaction Scope

Category Official Regulatory Information
Medicinal Product Categories Central Nervous System (CNS) depressants; medicines known to affect renal clearance.
Specific Interacting Medicines Ritonavir, Theophylline.
Population-Specific Notes The risk of adverse reactions is greater in patients with impaired renal function due to substantial renal excretion; the medicine is Contraindicated in individuals with End-Stage Renal Disease (ESRD).
Interaction-Related Restrictions Concurrent use with Alcohol and other CNS depressants must be avoided due to the officially documented risk of additional impairment of CNS performance and reduced alertness.

Interaction Classifications

Category Official Regulatory Classification/Statement
Interaction Severity Contraindicated combination (for specific patient conditions); Avoidance advised (for additive effects).
Food Interaction Context Administration with food does not alter the extent of exposure (AUC) of the tablet. However, the regulatory documentation states that the maximum concentration (Cmax) is reduced by approximately 36% and the time to maximum concentration (Tmax) is delayed by about 1.25 hours.

Resulting Interaction Structure

The official label notes that the co-administration of Ritonavir may lead to a reduced clearance and increased exposure of the antihistamine. The pharmacodynamic constraint is a clear restriction: the drug must be avoided with alcohol and other CNS depressants due to documented additive effects. The PK profile creates restrictions tied directly to renal function.

Mechanism of Action

Targeting the Bacterial Genome

Arlevo (levofloxacin) operates as an inhibitor of two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By forming stable, toxic complexes with these enzymes and the bacterial DNA strands, the drug directly interferes with the critical intracellular processes required for DNA replication, repair, and the separation of daughter chromosomes.

Initiating the Cell Death Cascade

The blockage of these enzymes prevents the necessary re-sealing of the bacterial DNA, leading to the accumulation of irreversible DNA double-strand breaks. This extensive genetic damage initiates a bacterial cell death cascade (bactericidal action). The consequence of this cellular destruction is a reduction in the viable bacterial population within the host system.

Understanding Mechanism Constraints

The mechanism's potential for action is structurally constrained by bacterial counter-mechanisms, primarily genetic mutations that alter the target enzyme binding sites or increased activity of efflux pumps that actively expel the drug, leading to reduced intracellular concentration and a constrained mechanistic cascade.

Dosage and Administration Information

Official Administration Guidelines

Arlevo (levocetirizine dihydrochloride) is for the oral route of administration, available as a 5 mg scored tablet and an oral solution (0.5 mg/mL). The tablets are designed to be breakable, allowing for administration of the 2.5 mg dose when needed. Administration can occur with or without food consumption, as absorption is not significantly affected by meals.

Dosing and Frequency

The standard regimen for adults and adolescents 12 years of age and older is 5 mg once daily, taken as a single dose. Guidelines generally recommend taking the dose in the evening. The maximum daily intake must not exceed 5 mg. For certain patients, a lower daily dose of 2.5 mg may provide adequate control. The use pattern can be intermittent for short-lived episodes or continuous for the full duration of allergen exposure, based on the nature of the condition.

Population-Specific Dosing Rules

Mandatory dose adjustment is required for patients 12 years and older with documented renal impairment, as the medicine is primarily cleared by the kidneys. The prescribed dose and frequency are reduced according to the patient’s specific creatinine clearance level. For patients presenting with solely hepatic impairment, no dose adjustment is typically indicated. For children aged 6 to 11 years, the dose is 2.5 mg once daily in the evening, which must not be surpassed.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Combination Therapy (Drug A + Drug B)

Studies have explored whether the combination of Drug A and Drug B was evaluated in the context of acute pain symptom reporting. Research has also evaluated outcomes associated with the combination in post-operative recovery settings.

  • Dose Regimens: Trials examined the administration of the lowest dose in a randomized-controlled setting to investigate outcomes observed in post-surgical pain.
  • Time-to-Onset Analysis: One study investigated whether this regimen was evaluated regarding differences in pain scores within the first 24 hours post-surgery, compared to monotherapy.

The research documentation noted a finding of reduced inflammatory markers, with the research team concluding that further investigation into potential long-term benefits may be warranted.


Evidence for Monotherapy (Drug C)

Research has investigated Drug C where research protocols focused on chronic neuropathic pain, and comparative studies examined whether its profile was compared to that of other treatment options. Findings from these non-randomized studies were mixed regarding sustained symptom management.

  • Off-Label Exploration: Several independent research projects have looked at the role of Drug C in complex regional pain syndrome (CRPS) research, a focus for which evidence is currently limited.
  • Safety Profile: The safety profile of Drug B was explored, and studies included patients receiving the drug for long-term use. Caution was noted in individuals with kidney problems. The results observed in elderly patient populations were comparable to those in younger cohorts.

Key Studies & References

  1. Optimal multimodal analgesia combinations to reduce pain and opioid use following non-cardiac surgery
  2. Systematic Review and Meta-Analysis of Anti-Inflammatory Markers in Response to Common Analgesic Drug Classes (Used to support inflammatory markers claim)

Frequently Asked Questions (FAQ)

Common questions about Arlevo (FAQ)

Q: Is Arlevo a steroid?

According to official drug classifications, Arlevo (levocetirizine dihydrochloride) is not a steroid. It belongs to the class of medications known as antihistamines, which work by blocking the effects of histamine in the body.


Q: Does Arlevo cause weight gain?

Weight gain is not commonly listed as one of the most frequently reported side effects in official regulatory documents. However, weight gain has been reported as an uncommon side effect in certain clinical contexts.


Q: What is Arlevo usually prescribed for?

The official uses for Arlevo are defined in the regulatory labeling as the relief of symptoms associated with perennial and seasonal allergic rhinitis (hay fever). It is also indicated for the treatment of the skin manifestations of chronic idiopathic urticaria (hives).


Q: Are there any long-term effects of taking Arlevo?

Official documents include warnings about potential effects that can be associated with stopping the drug after long-term daily use. Reports describe instances of severe itching (pruritus) upon discontinuation in some patients who used the medication daily for several months or years.


Q: What are the most common side effects of Arlevo?

Regulatory documents indicate that the most frequently reported side effects in adult clinical studies include sleepiness or drowsiness, fatigue, dry mouth, and inflammation of the nose or throat (nasopharyngitis). These findings are based on controlled patient data.


Q: Why do some people stop taking Arlevo?

Based on regulatory documentation from clinical trials, sleepiness (somnolence) was reported as the most common reason for patients to discontinue the medication.


Q: Is Arlevo used for anxiety or depression?

The official regulatory indications define the drug's use for symptoms related to allergic rhinitis and chronic idiopathic urticaria (hives). It is not officially indicated for anxiety or depression.


Q: Does Arlevo interact with birth control pills?

Official drug interaction documents do not specifically list hormonal birth control pills as an interacting medicine that affects the safety or efficacy of Arlevo.


Q: What should I do if a side effect seems serious?

Official patient information advises that one should seek immediate medical help if signs of a severe allergic reaction occur, such as swelling of the face, tongue, or throat. Seeking immediate care is also advised if difficulty urinating occurs.


Q: Is Arlevo a controlled substance?

Official drug scheduling records confirm that Arlevo (levocetirizine dihydrochloride) is not classified as a controlled substance.


Q: Does taking Arlevo affect blood pressure?

Official reports on adverse reactions do not commonly list significant effects on blood pressure among the most frequently observed or serious side effects of the medication.


Q: Is Arlevo safe to use during pregnancy?

Official product information advises that there are no adequate and well-controlled studies conducted in pregnant women. Official advice states the drug should only be used if clearly needed.


Q: Does Arlevo cause stomach upset or nausea?

Official data indicates that gastrointestinal upset, such as vomiting and diarrhea, has been reported in children in clinical trials. However, nausea is generally not listed as a highly common adverse event in adult studies.


Q: What research evidence supports the use of Arlevo?

Regulatory approval for the drug is based on clinical trial evidence submitted by the manufacturer. These studies demonstrated the drug's effectiveness in reducing symptoms of allergic rhinitis and chronic idiopathic urticaria compared to an inactive placebo.


Q: Can I get Arlevo over the counter?

The drug is officially available in both prescription-only and over-the-counter (OTC) formulations, depending on the country and specific product. This dual availability is reflected in regulatory approval history.


Q: Does Arlevo expire?

As a regulated medication, the product packaging is required by authorities to display an expiration date. Medications should not be used past the date printed on the packaging.


Q: Can Arlevo cause dry mouth?

Yes, dry mouth is officially listed as one of the common side effects reported in clinical studies of the drug.


Q: Is Arlevo addictive?

No, Arlevo is not classified as a controlled substance. Official documentation does not indicate that the drug has addiction or dependence potential.


Q: What if I take too much Arlevo by accident?

Official patient information advises seeking immediate medical help or contacting a Poison Control Center right away in case of overdose.


Q: Does Arlevo affect fertility?

Official human labeling does not directly provide information on effects on human fertility. However, non-clinical animal studies conducted by the manufacturer did not indicate a risk to fertility at doses relevant to human use.


Q: Is there a generic version of Arlevo available?

Yes, regulatory records confirm that a generic version containing the active ingredient, levocetirizine dihydrochloride, is officially available.


Q: How should Arlevo be stored?

Official labels typically instruct that the tablets should be stored at controlled room temperature. This temperature is usually defined as between 20 and 25 C (68 and 77 F).


Q: What are the less common side effects of Arlevo?

Less common side effects reported in official clinical trials include difficulty emptying the bladder (urinary retention), vision problems such as blurred vision, and severe weakness (asthenia).


Q: Can Arlevo cause dizziness?

Yes, dizziness or lightheadedness are officially listed among the reported side effects in clinical studies of the medication.


Q: Why is Arlevo only available by prescription?

While the drug has both prescription and non-prescription status globally, it was initially approved as a prescription drug. This was due in part to the need for professional guidance, particularly concerning dose adjustment for patients with kidney impairment.


Q: What is the difference between Arlevo and a placebo in studies?

Clinical trial results submitted for regulatory approval demonstrated that Arlevo was superior to a placebo in reducing allergy symptoms in study participants. A placebo is an inactive substance used for comparison in studies.


Q: Is Arlevo a brand name or a generic name?

Arlevo is a brand name for the medication. The official generic name of the active ingredient is levocetirizine dihydrochloride.


Q: What are the main risks associated with Arlevo?

Official warnings and precautions highlight several risks, including the potential for central nervous system effects (such as drowsiness), difficulty urinating, and the necessity for dose adjustment in patients with kidney impairment.


Q: Can people with heart conditions use Arlevo?

The label notes that cautious dose selection is warranted for elderly patients, reflecting the more frequent occurrence of decreased kidney and cardiac function in this population. However, heart conditions are not listed as a general contraindication for the drug's use.


Q: How soon after starting Arlevo might I feel better?

Official product information notes that food may delay the time it takes for the drug to reach its maximum concentration in the blood. However, specific information regarding the exact time to onset of therapeutic effect is not explicitly included in the main regulatory documents.


Q: Can Arlevo be taken with painkillers?

Official warnings advise avoiding use with alcohol and other CNS depressants due to the risk of increased impairment of alertness. Painkillers are a broad category, and the potential for interaction depends on whether the painkiller contains CNS depressants or other interacting substances.


Q: Does Arlevo affect sleep?

Official warnings indicate that the drug may cause drowsiness or reduced alertness. Official guidelines often suggest taking the dose in the evening due to the potential for central nervous system effects and reduced alertness.


Q: Can older people use Arlevo?

Official guidelines note that older patients may require dose adjustment, reflecting the need for professional evaluation. This is necessary because age-related decreases in kidney function may require a mandatory dose change.


Q: Are there any food restrictions with Arlevo?

Regulatory documents state that taking the tablet with food does not alter the total amount of the drug absorbed. However, food is documented to delay the time it takes for the drug to reach its maximum concentration in the bloodstream.


Q: How is Arlevo different from an opioid?

Arlevo is classified as an antihistamine, which works by blocking histamine receptors to relieve allergy symptoms. Opioids are a class of drugs that act on the central nervous system to relieve pain, making them fundamentally different drug classes.


Q: What does 'contraindication' mean for Arlevo?

The term 'contraindication' refers to specific conditions or circumstances where a medicine should not be used because the risk outweighs any potential benefit. For Arlevo, an example of a contraindication is End-Stage Renal Disease (ESRD).


Q: Can I stop taking Arlevo suddenly?

Official documents describe the drug's use as either intermittent or continuous. However, recent warnings highlight that stopping the medication abruptly after long-term daily use may result in a side effect of severe itching (pruritus).


Q: Can Arlevo be taken with common cold medicines?

Official regulatory warnings advise avoiding co-administration with other medicines that are known to cause drowsiness or decreased alertness (CNS depressants). Many common cold and flu preparations contain such ingredients.


Q: Is it normal to feel tired when first starting Arlevo?

The most commonly reported side effects in clinical trials include drowsiness and fatigue. Official guidelines often suggest taking the dose in the evening, reflecting this potential side effect.


Q: How long do most people stay on Arlevo?

The official documentation indicates that the use pattern can be intermittent for short-lived allergy episodes or continuous for the full duration of a patient's allergen exposure.


Q: What does the drug class of Arlevo mean?

The official drug class of Arlevo is 'Histamine H1-receptor antagonist,' commonly known as a second-generation antihistamine. This class of medication works to relieve symptoms by blocking the effects of the natural substance histamine.

How should Arlevo be stored and disposed of?

Official Storage and Handling

Arlevo (levofloxacin) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in the container it came in, with the container tightly closed, and stored away from excess heat, moisture, and light. To maintain the product's stability, do not freeze Arlevo tablets. Always inspect the product for an intact seal before use. All medicines, including Arlevo, must be stored out of the reach of children and pets to prevent accidental ingestion.

Disposal Requirements

Dispose of any outdated or unused Arlevo as soon as it is no longer needed. Do not flush the tablets down a toilet or throw them into household trash unless specific instructions permit. The preferred method for discarding is to utilize a secure medicine take-back program or pharmacy collection point. If these options are unavailable, follow the safe disposal guidelines provided by your healthcare professional or local government authority to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arlevo found in:

A-Z Index: